Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) EPS (Basic): 2012-2025

Historic EPS (Basic) for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $1.42.

  • CorMedix's EPS (Basic) rose 2940.00% to $1.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.27, marking a year-over-year increase of 415.28%. This contributed to the annual value of -$0.30 for FY2024, which is 67.03% up from last year.
  • Per CorMedix's latest filing, its EPS (Basic) stood at $1.42 for Q3 2025, which was up 389.66% from $0.29 recorded in Q2 2025.
  • In the past 5 years, CorMedix's EPS (Basic) ranged from a high of $1.42 in Q3 2025 and a low of -$0.25 during Q2 2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.11 (2023), whereas its average is $0.11.
  • As far as peak fluctuations go, CorMedix's EPS (Basic) plummeted by 58.33% in 2022, and later spiked by 2,940.00% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's EPS (Basic) stood at -$0.21 in 2021, then increased by 4.76% to -$0.20 in 2022, then remained steady at -$0.17 in 2023, then skyrocketed by 70.59% to $0.24 in 2024, then soared by 2,940.00% to $1.42 in 2025.
  • Its EPS (Basic) was $1.42 in Q3 2025, compared to $0.29 in Q2 2025 and $0.32 in Q1 2025.